查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529816

结核病诊断市场规模、份额、趋势分析报告：按测试类型、最终用途、地区、细分市场预测，2024-2030 年

Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Nucleic Acid Testing, Detection of Latent Infection), By End-use (Diagnostic Laboratories, Hospitals), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

结核病诊断市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球结核病诊断市场规模预计将达到32.9亿美元，2024年至2030年复合年增长率为5.97%。

干扰素-γ释放测定（IGRA）、血清学技术和核酸检测等先进诊断技术的出现导致了诊断剂的高利用率。此外，抗原检测等护理点 (POC) 技术也提高了结核病的诊断率。

这些先进的方法，包括 POC 诊断，价格实惠、准确、方便，并且可以快速提供结果。此外，结核病负担的增加是推动市场成长的主要因素。根据世界卫生组织（WHO）估计，2014年全球结核病患者人数约960万人。这种高盛行率促使政府、医疗机构、研究机构和市场相关人员采取措施遏制这种感染疾病的爆发。

发展重点是提高高负担地区的筛检率、负担得起的诊断、先进的调查方法、快速的临床决策和降低死亡率。提高预防性和治疗性诊断率是这些努力的最终结果。因此，诊断测试的需求迅速增加，结核病诊断市场不断扩大。

结核病诊断市场报告亮点

  • 诊断测试在 2023 年将占 46.92% 的份额，因为它们具有成本效益且易于执行。诊断实验室测试包括涂片显微镜检查和基于培养的测试。高负担地区缺乏采用先进技术并依赖这些方法的财政和技术能力，从而促进了诊断实验室检测行业的成长。
  • 然而，准确度低和处理时间长是此诊断方法的限制因素。因此，医疗机构努力在发展中地区实施先进技术。
  • 因此，核酸检测领域和潜在感染疾病检测领域，包括皮肤检测和IGRA，可能呈现盈利成长率。这些方法透过克服上述限制来提高诊断的负担能力、处理时间和准确性。
  • 结核病的抗药性是医疗专业人员关注的主要问题之一，因为错误的用药方案或错误的剂型导致治疗不当，导致结核病患者在治疗过程中产生抗药性。因此，抗药性检测领域也预计将呈现良好的成长动能。
  • 亚太地区人口众多、结核病患率高，在2015年主导了全球结核病诊断市场。世界卫生组织表示，印度、中国、阿富汗和印尼等国家是控制这场疫情的优先地区。
  • 新产品发布、联盟、併购和区域扩张是这些产业参与者采取的主要策略措施。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章结核病诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 结核病诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章结核病诊断市场：按测试类型进行估计和趋势分析

  • 全球结核病诊断市场：按测试类型分類的仪表板
  • 全球结核病诊断市场：按测试类型分析差异
  • 全球结核病诊断市场：按测试类型分類的收益
  • 核酸检测
  • 检测潜伏感染（皮肤试验和IGRA）
  • 抗药性检测（DST）
  • 噬菌体测定
  • 细胞激素检测分析
  • 诊断测试方法
  • 放射学方法
  • 其他方法

第五章结核病诊断市场：最终用途的估计和趋势分析

  • 全球结核病诊断市场：依最终用途分類的仪表板
  • 全球结核病诊断市场：最终用途的变化分析
  • 全球结核病诊断市场：按最终用途分類的收益
  • 诊断实验室
  • 医院和诊所
  • 其他的

第六章结核病诊断市场：按测试类型和最终用途分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • BD
    • F. Hoffmann-La Roche AG
    • Hologic, Inc.
    • Cepheid
    • DiaSorin SpA
    • Hain Lifescience GmbH
    • Oxford Immunotec
Product Code: GVR-1-68038-098-9

Tuberculosis Diagnostics Market Growth & Trends:

The global tuberculosis diagnostics market size is expected to reach USD 3.29 billion by 2030, registering a CAGR of 5.97% from 2024 to 2030, according to a new report by Grand View Research, Inc. Advent of advanced diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological methods, and nucleic acid testing have resulted in the high usage rate of diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays are also promoting the diagnosis rate of TB.

These advanced methods including POC diagnostics are affordable, accurate, simple, and yield quick results. Furthermore, the rising burden of TB is the primary factor responsible for the lucrative market growth. As per the World Health Organization, the global estimates of patients afflicted with TB were around 9.6 million in 2014. This high prevalence rate has led the government, healthcare organizations, research institutes, and market players to initiate endeavors directed toward containing the incidence of this infectious disease.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.

Tuberculosis Diagnostics Market Report Highlights:

  • Diagnostic laboratories dominated the test type segment with of 46.92% in 2023 as they are cost efficient and easy-to-perform. Diagnostic laboratory tests include smear microscopy and culture-based tests. The high burden regions rely on these methodologies due to their financial and technical incapability to incorporate advanced technologies thus contributing to the growth of the diagnostic laboratory tests segment.
  • However, compromised accuracy and the longer processing time are the limiting factor for the diagnostics. Hence, healthcare agencies are striving to implement advanced techniques in the developing regions.
  • As a result, nucleic acid tests segment and the latent infection detection segment, which includes skin tests and IGRA, are likely to exhibit a profitable growth rate. These methods overcome the aforementioned limitations thus improving affordability, processing time and accuracy of the diagnostic method.
  • Drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimen and incorrect dosage forms lead to the development of drug resistance in TB patients undergoing treatment. Hence, the drug resistance detection segment is also anticipated to witness lucrative growth.
  • Asia Pacific owing to its huge population base and high burden of TB dominated the global TB diagnostics market in 2015. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for control of this communicable disease.
  • New product launches, collaboration, mergers & acquisitions, and regional expansion are the key strategic initiatives undertaken by these industry players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. End-use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type and end-use outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Tuberculosis Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of TB
      • 3.2.1.2. Increasing funding program for TB diagnosis
      • 3.2.1.3. Favorable government initiatives for combating TB
      • 3.2.1.4. Surge in geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
  • 3.3. Tuberculosis Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Tuberculosis Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Global Tuberculosis Diagnostics Market: Test Type Dashboard
  • 4.2. Global Tuberculosis Diagnostics Market: Test Type Movement Analysis
  • 4.3. Global Tuberculosis Diagnostics Market by Test Type, Revenue
  • 4.4. Nucleic Acid Testing
    • 4.4.1. Nucleic acid testing market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.5. Detection of Latent Infection (Skin Test & IGRA)
    • 4.5.1. Detection of latent infection (skin test & IGRA) market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.6. Detection of Drug Resistance (DST)
    • 4.6.1. Detection of Drug Resistance (DST) market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.7. Phage Assay
    • 4.7.1. Phase assay market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.8. Cytokine Detection Assay
    • 4.8.1. Cytokine detection assay market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.9. Diagnostic Laboratory Methods
    • 4.9.1. Diagnostic laboratory methods market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.10. Radiographic Method
    • 4.10.1. Radiographic method market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 4.11. Other Methods
    • 4.11.1. Other methods market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests)

Chapter 5. Tuberculosis Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. Global Tuberculosis Diagnostics Market: End Use Dashboard
  • 5.2. Global Tuberculosis Diagnostics Market: End Use Movement Analysis
  • 5.3. Global Tuberculosis Diagnostics Market by End-use, Revenue
  • 5.4. Diagnostic Laboratories
    • 5.4.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 5.5. Hospitals and Clinics
    • 5.5.1. Hospitals and clinics market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Volume, Number of Tests)
  • 5.6. Others
    • 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests)

Chapter 6. Tuberculosis Diagnostics Market: Regional Estimates & Trend Analysis by Test Type, and End-use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests) (Number of Tests)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Abbott
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. QIAGEN
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Thermo Fisher Scientific Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. BD
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. F. Hoffmann-La Roche AG
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Hologic, Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Cepheid
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. DiaSorin S.p.A.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Hain Lifescience GmbH
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Oxford Immunotec
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 4 Global Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 5 Global Nuclear Magnetic Resonance Spectroscopy, by Region, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 6 North America Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 7 North America Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 8 North America Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 9 U.S. Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 10 U.S. Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 11 Canada Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 12 Canada Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 13 Mexico Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 14 Mexico Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 15 Europe Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 16 Europe Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 17 Europe Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 18 Germany Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 19 Germany Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 20 UK Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 21 UK Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 22 France Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 23 France Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 24 Italy Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 25 Italy Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 26 Spain Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 27 Spain Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 28 Denmark Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 29 Denmark Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 30 Sweden Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 31 Sweden Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 32 Norway Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 33 Norway Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 34 Asia Pacific Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 35 Asia Pacific Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 36 Asia Pacific Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 37 China Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 38 China Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 39 Japan Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 40 Japan Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 41 India Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 42 India Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 43 South Korea Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 44 South Korea Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 45 Australia Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 46 Australia Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 47 Thailand Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 48 Thailand Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 49 Latin America Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 50 Latin America Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 51 Latin America Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 52 Brazil Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 53 Brazil Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 54 Argentina Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 55 Argentina Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 56 Middle East & Africa Nuclear Magnetic Resonance Spectroscopy, by Country, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 57 Middle East & Africa Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 58 Middle East & Africa Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 59 South Africa Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 60 South Africa Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 61 Saudi Arabia Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 62 Saudi Arabia Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 63 UAE Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 64 UAE Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 65 Kuwait Nuclear Magnetic Resonance Spectroscopy, by Test Type, 2018 - 2030 (USD Million) (Number of Tests)
  • Table 66 Kuwait Nuclear Magnetic Resonance Spectroscopy, by End Use, 2018 - 2030 (USD Million) (Number of Tests)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Tuberculosis Diagnostics Market Segmentation
  • Fig. 8 Market Snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Global Tuberculosis Diagnostics Market: Test Type Movement Analysis
  • Fig. 16 Global Tuberculosis Diagnostics Market, Nucleic Acid Testing, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 17 Global Tuberculosis Diagnostics Market, Detection of Latent Infection (Skin Test & IGRA), 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 18 Global Tuberculosis Diagnostics Market, Detection of Drug Resistance (DST), 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 19 Global Tuberculosis Diagnostics Market, Phage Assay, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 20 Global Tuberculosis Diagnostics Market, Cytokine Detection Assay, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 21 Global Tuberculosis Diagnostics Market, Diagnostic Laboratory Methods, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 22 Global Tuberculosis Diagnostics Market, Radiographic Method, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 23 Global Tuberculosis Diagnostics Market, Other Methods, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 24 Global Tuberculosis Diagnostics Market: End Use Movement Analysis
  • Fig. 25 Global Tuberculosis Diagnostics Market, for Diagnostics Laboratories, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 26 Global Tuberculosis Diagnostics Market, for Hospitals and Clinics, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 27 Global Tuberculosis Diagnostics Market, for Others, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 Regional Outlook, 2023 & 2030
  • Fig. 30 Global Tuberculosis Diagnostics Market: Region Movement Analysis
  • Fig. 31 North America Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 32 U.S. Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 33 Canada Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 34 Mexico Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 35 Europe Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 36 Germany Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 37 UK Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 38 France Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 39 Italy Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 40 Spain Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 41 Denmark Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 42 Sweden Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 43 Norway Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 44 Asia Pacific Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 45 Japan Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 46 China Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 47 India Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 48 Australia Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 49 South Korea Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 50 Thailand Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 51 Latin America Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 52 Brazil Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 53 Argentina Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 54 Middle East and Africa Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 55 South Africa Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 56 Saudi Arabia Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 57 UAE Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)
  • Fig. 58 Kuwait Tuberculosis Diagnostics Market, 2018 - 2030 (USD Million) (Number of Tests)